This fact is consistent with the literature data, according to which a higher level of IL-2 in the blood serum of patients with breast cancer is due to its role in increasing the survival and proliferation of activated CD8+ T-cells, which in turn leads to an increase in the overall cytotoxic response [48]. This evidence concerns the gene IL2 and breast carcinoma.